MOLECULAR ONTOGENY OF ORAL MUCOSAL RESISTANCE TO SIV

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 西塔防御素是在东半球猴子的白细胞中产生的宿主防御肽(但在黑猩猩或人类中不存在；参见下面的参考文献)。在小鼠和大鼠身上进行的实验中，theta防御素有助于清除实验感染中的细菌，并大大减少全身炎症(严重脓毒症)的致命影响。我们的长期目标是确定theta防御素作为人类疗法的适用性。 两只成年黑猩猩将接受分级(递增)静脉注射自然产生的Theta-Defensin RTD-1剂量)。这些实验的目的是1)确定治疗是否有任何急性或亚急性毒性，2)确定注射的蛋白质是否在黑猩猩中引起抗体反应，3)确定其他免疫介质(细胞因子)是否受到治疗的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Theta defensins are host defense peptides produced in the white blood cells of Old World monkeys (but not in chimpanzees or humans; see references below). In experiments performed in mice and rats, theta defensins facilitate clearance of bacteria in experimental infections, and also profoundly reduce the lethal effects of systemic inflammation (severe sepsis). Our long term goal is to determine the suitability of theta defensins as human therapeutics. Two adult chimpanzees will receive graded (increasing), intravenously administered doses of a naturally occurring theta-defensin RTD-1). The goal of these experiments are 1) to determine if there is any acute or subacute toxicity associated with the treatment, 2) to determine whether the administered protein elicits an antibody response in the chimpanzees, and 3) to determine whether other immunologic mediators (cytokines) are affected by the treatments.